Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:30AM EDT. Market open.
| Previous close | 202.46 |
| Open | 201.22 |
| Bid | 205.49 x 100 |
| Ask | 206.10 x 100 |
| Day's range | 199.10 - 205.93 |
| 52-week range | 189.44 - 319.76 |
| Volume | |
| Avg. volume | 1,260,329 |
| Market cap | 29.982B |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | 25.74 |
| EPS (TTM) | 8.00 |
| Earnings date | 23 July 2024 - 29 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 286.10 |
ZacksThe Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
GuruFocus.comDecoding Biogen Inc (BIIB): A Strategic SWOT Insight
Insightful Analysis of Biogen Inc's Financials and Strategic Positioning
GlobeNewswireBiogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFID
© 2024 Yahoo. All rights reserved.